IN8bio (INAB) Corporate presentation summary

Company overview and leadership

• Clinical-stage biotech focused on gamma-delta T cell therapies for autoimmune diseases and cancer.

• Leadership team brings 35+ years of gamma-delta T cell expertise and deep experience in oncology, immunology, and business development.

Pipeline and clinical programs

• Pipeline includes T cell engagers (TCEs) for autoimmune and oncology indications, and cellular therapies for leukemias and solid tumors.

• INB-619 is a pan-gamma-delta CD19 TCE in IND-enabling studies, with initial animal data expected in 2026.

• INB-100 targets AML, while INB-200/400 are drug-resistant immunotherapies for glioblastoma, with ongoing and completed clinical trials.

Scientific rationale and differentiation

• Gamma-delta T cells offer innate and adaptive immune activity, high durability, and lower risk of side effects compared to CAR-T and CD3 TCEs.

• INB-619 selectively activates gamma-delta T cells, minimizing cytokine release syndrome and immune exhaustion, and achieves deeper B cell depletion.

• INB-619 depletes B cells without the toxicity seen in CD3 TCEs, expanding both Vδ1 and Vδ2 subtypes for broader tissue and blood targeting.